Newsfiscal.ai
Cerenome Announces New Preclinical Data for REYOBIQ™ at Rivkin Ovarian Cancer Research Symposium
· Published
Article summary
Cerenome, Inc. reported new preclinical data demonstrating the immunomodulatory properties of its lead radiotherapeutic candidate, REYOBIQ™, in ovarian cancer models.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…